Moving iMage Technologies Reports Revenue of $3.57M, Improved Q3 Gross Profit and Reduced Net Loss; Net Cash Steady at $5.4M at Quarter End
Q3'25 Highlights
Q3'25 revenue declined 8.2% to $3.571M vs. $3.890M in Q3'24, principally due to customer delays in the commencement of several projects that are now expected later in Q4'25 or FY 2026.
Q3'25 gross profit dollars increased $387K to $1.063M vs. $676K in Q3'24, reflecting the benefit of a focus on higher margin project and product opportunities as well as the impact of lower margin cinema facilities equipment sales and certain inventory reserves in Q3'24.
Q3'25 gross margin percentage increased to 29.8% vs. 17.4% in Q3'24 due to the absence of lower margin cinema facilities equipment revenue in Q3'24.
Q3'25 operating loss improved to ($270K) vs. ($649K) in Q3'24, principally reflecting the gross margin improvement.
Q3'25 net loss improved to ($240K), or ($0.02) per share, vs. ($601K) or ($0.06) per share, in Q3'24.
Net cash steady at $5.4M, or approximately $0.54 per common share, and there was no long-term debt as of 3/31/25.
Moving Image Chairman and CEO, Phil Rafnson, commented, "In the face of business and economic uncertainties impacting our customers' near-term spending decisions, we remain focused on building our project pipeline with new and existing customers while also working to reduce expenses, focus on higher margin opportunities and preserving our cash position. Despite these transitory impacts, we remain confident in the substantial longer term business potential of the cinema technology refresh cycle involving the replacement of thousands of legacy cinema projectors and sound systems with state-of-the-art laser projectors and updated sound systems over the next few years."
President and COO, Francois Godfrey, added, "Ongoing customer dialogues confirm the need, customer experience and operating cost benefits of new laser projection systems. Further, our team's long-term experience, strong reputation and unrivaled ability to design and execute projects in any entertainment environment positions us well to earn a significant share of this activity. A perfect example was the decision to select Moving iMage to design and implement a state-of-the-art, seven-screen theater complex at Cannon Beach in Arizona. We expect installation work to commence early in fiscal 2026 and are very proud to play a defining role in this unique, complex and high-profile project with outstanding business partners."
"We came away from CinemaCon in late April with new relationships, opportunities and ideas to maximize efficiencies and are proud to repeatedly overdeliver on client needs from coast to coast. Recent new business wins include a $9M projector technology refresh contract spread over three years for an important long-term exhibition customer, the Cannon Beach project mentioned by Phil, and several other pending turnkey cinema deployments.
"While current economic uncertainties are slowing the pace of projects and customer decision making, we have built a base of $8M to $9M in largely recurring annual revenue, a solid pipeline of contracted projects and a significant number of opportunities in development, most of which we expect in fiscal 2026 or future years. We are focused on the things that we can control, principally our overhead, product and service margins and pace of investment, to ensure that we remain well positioned to pursue growth opportunities and make progress on our goal to move the business to positive cash flow and profitability.
"We currently expect Q4'25 revenue of approximately $5.2M, as a result of some larger FY 2025 projects getting pushed into FY 2026, and solid progress in the reduction of our net loss on a sequential and year-over-year basis. Looking into FY 2026, while we are encouraged by the recent box office gains, we look forward to our customers updating their auditoriums with higher image quality and lower total cost of ownership of new cinema systems."
Conference Call Details
Dial-in Number: 1-877-407-4018
Toll/International Number: 1-201-689-8471
Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ Link for instant telephone access to the event. Call me™ link will be made active 15 minutes prior to scheduled start time.
Transcript: Posted online here 48 hours after the event
Questions can be submitted in advance via Email to: mitq@catalyst-ir.com
Telephone Replay
Access ID: 13753795
Replay Dial-In: 1-844-512-2921 or 1-412-317-6671
Replay Expiration: Thursday May 29, 2025 at 11:59 p.m. ET
Forward-Looking Statements
All statements above that are not purely about historical facts, including, but not limited to, those in which we use the words "believe," "anticipate," "expect," "plan," "intend," "estimate," "target" and similar expressions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. While these forward-looking statements represent our current judgment of what may happen in the future, actual results may differ materially from the results expressed or implied by these statements due to numerous important factors. Our filings with the SEC provide detailed information on such statements and risks and should be consulted along with this release. To the extent permitted under applicable law, we assume no obligation to update any forward-looking statements.
About Moving iMage Technologies (www.movingimagetech.com)
With a focus on innovation, service, and quality, Moving iMage Technologies ("MiT") is a trusted partner in delivering state-of-the-art out-of-home entertainment environments. Founded in 2003, MiT provides products, integrated systems design, custom engineering, proprietary products, software, and installation services for cinemas, screening rooms, postproduction facilities, high-end home theaters, Esports venues, arenas, stadiums, and other entertainment spaces.
MiT manufactures a broad line of digital cinema peripherals in the U.S., including automation systems, projector pedestals/bases, projector lifts, hush boxes, direct-view LED frames, lighting fixtures and dimmers, power management devices, operations software, and Esports platforms. It also distributes and integrates cinema equipment from Barco, Sharp (NEC) Digital Cinema, Christie Digital, LEA Professional, Dolby, GDC, JBL/Crown, LG, Meyer Sound, Q-SYS, QSC, Samsung and others.
MiT's Caddy Products division designs and sells cupholders, concession trays, and venue accessories that enhance concession sales and improve the guest experience.
MOVING IMAGE TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share amounts)
March 31,
June 30,
2025
2024
(unaudited)
Assets
Current Assets:
Cash $ 5,369
$ 5,278
Accounts receivable, net
940
1,048
Inventories, net
3,065
3,117
Prepaid expenses and other
241
470
Total Current Assets
9,615
9,913
Long-Term Assets:
Right-of-use asset
1,142
144
Property and equipment, net
18
28
Intangibles, net
378
422
Other assets
15
16
Total Long-Term Assets
1,553
610
Total Assets $ 11,168
$ 10,523
Liabilities And Stockholders' Equity
Current Liabilities:
Accounts payable $ 2,745
$ 2,261
Accrued expenses
351
320
Customer refunds
288
399
Customer deposits
1,534
1,651
Lease liability-current
219
151
Unearned warranty revenue
53
31
Total Current Liabilities
5,190
4,813
Long-Term Liabilities:
Lease liability-non-current
979
-
Total Long-Term Liabilities
979
-
Total Liabilities
6,169
4,813
Stockholders' Equity
Common stock, $0.00001 par value, 100,000,000 shares authorized, 9,933,679 and 9,896,850 shares issued and outstanding at March 31, 2025 and June 30, 2024, respectively
-
-
Additional paid-in capital
12,047
11,965
Accumulated deficit
(7,048)
(6,255)
Total Stockholders' Equity
4,999
5,710
Total Liabilities and Stockholders' Equity $ 11,168
$ 10,523
The accompanying notes are an integral part of these condensed consolidated financial statements.
MOVING IMAGE TECHNOLOGIES, INC.
(in thousands except share and per share amounts)
(unaudited)
Three Months Ended
Nine Months Ended
March 31,
March 31,
2025
2024
2025
2024
Net sales $ 3,571
$ 3,890
$ 12,264
$ 13,790
Cost of goods sold
2,508
3,214
8,894
10,536
Gross profit
1,063
676
3,370
3,254
Operating expenses:
Research and development
49
73
157
212
Selling and marketing
429
547
1,421
1,717
General and administrative
855
705
2,691
2,421
Total operating expenses
1,333
1,325
4,269
4,350
Operating (loss)
(270)
(649)
(899)
(1,096)
Other income (expense)
Interest and other income, net
30
48
107
140
Total other income
30
48
107
140
Net (loss) $ (240) $ (601) $ (792) $ (956)
Weighted average shares outstanding: basic and diluted
9,911,015
10,436,519
9,901,554
10,593,229
Net (loss) income per common share basic and diluted $ (0.02) $ (0.06) $ (0.08) $ (0.09)
The accompanying notes are an integral part of these condensed consolidated financial statements.
Nine Months Ended
March 31
2025
2024
Cash flows from operating activities:
Net (loss) $ (792) $ (956)
Adjustments to reconcile net (loss) to net cash provided by (used in) operating activities:
Provision for credit losses
59
(52)
Inventory reserve
277
433
Depreciation expense
10
9
Amortization expense
44
43
Right-of-use amortization
197
201
Stock option compensation expense
59
15
Stock issued for director expenses
23
13
Changes in operating assets and liabilities
Accounts receivable
50
67
Inventories
(226)
(234)
Prepaid expenses and other
230
(487)
Accounts payable
484
(50)
Accrued expenses and customer refunds
(81)
129
Unearned warranty revenue
22
26
Customer deposits
(117)
726
Lease liabilities
(148)
(207)
Net cash provided by (used in) operating activities
91
(324)
Cash flows from investing activities
Purchases of property and equipment
-
(12)
Net cash (used in) investing activities
-
(12)
Cash flows from financing activities
Stock Buyback
-
(334)
Net cash (used in) financing activities
-
(334)
Net increase (decrease) in cash
91
(670)
Cash, beginning of the period
5,278
6,616
Cash, end of the period $ 5,369
$ 5,946
Non-cash investing and financing activities:
Right-of-use assets from new lease $ (207) $ -
Right-of-use assets from lease modification $ (988) $ -
The accompanying notes are an integral part of these condensed consolidated financial statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 minutes ago
- Globe and Mail
CVRx (CVRX) Q2 Revenue Jumps 15%
Key Points Revenue (GAAP) rose 15% to $13.6 million, surpassing both company expectations and analyst estimates. Net loss narrowed on a per-share basis to $(0.57) (GAAP), primarily due to a higher share count despite a slight increase in overall losses. These 10 stocks could mint the next wave of millionaires › CVRx (NASDAQ:CVRX), a medical device innovator focused on heart failure therapy, released its second quarter 2025 earnings on August 4, 2025. The most important news was a Revenue (GAAP) increased to $13.6 million, up 15% year-over-year and above analyst expectations of $13.29 million (GAAP). The company also reported a net loss of $14.7 million, or $(0.57) per share (GAAP). While that loss widened slightly, the per-share figure (GAAP) improved due to an increased share count. The quarter reflected strong commercial progress for its Barostim neuromodulation device despite heavy investment in sales and marketing. Results slightly exceeded internal and external expectations, and management narrowed its revenue guidance to a range of $55.0 million to $57.0 million. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS (GAAP) $(0.57) $(0.52) $(0.65) 12.3% Revenue (GAAP) $13.6 million $13.29 million $11.8 million 15.1% Gross Profit $11.5 million N/A N/A Gross Margin 84% 84% 0% Net Loss $14.7 million $14.0 million -5.0% Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. About CVRx and Its Core Business CVRx (NASDAQ:CVRX) specializes in developing implantable medical devices for treating heart failure. Its leading product, Barostim, is a neuromodulation device—meaning it delivers targeted electrical pulses to nerves in the carotid artery to improve function of the autonomic nervous system. This system regulates key bodily functions, including blood pressure and heart rate. Barostim is designed to treat patients with heart failure with reduced ejection fraction (HFrEF), providing an option that avoids direct implantation in the heart. The company's commercial priorities are building deep adoption in centers with strong heart failure programs and expanding reimbursement pathways to improve access. Solid clinical evidence and reliable regulatory support have been the company's main success factors, along with educating physicians and patients on Barostim's benefits. Quarter Highlights and Key Developments During the period, total revenue (GAAP) reached $13.6 million, outpacing both the company's guides and Wall Street expectations by over 2%. U.S. heart failure revenue remained the largest contributor, climbing to $12.1 million, with units up to 387 from 339 in the prior year. U.S. sales overall were $12.2 million, also up 15% (GAAP). Across the Atlantic, European revenue grew 19% to $1.3 million (GAAP), but the number of European implant units declined from 63 to 61, signaling some softness in procedural volume despite improved pricing or product mix. Active implanting centers in the U.S. grew to 240, reflecting 13 new centers added in the U.S. during the quarter. U.S. sales territories also grew to 47, up from 45, while European territories held steady at five. U.S. revenue accounted for approximately 89.8% of total sales (GAAP), indicating the company's primary growth engine remains domestic. The company attributes revenue gains to both new account additions and greater utilization per center, while the slightly lower European volumes point to variability in adoption across geographies. Gross profit (GAAP) grew 16% from the prior year, maintaining a gross margin of 84%. On the expense side, research and development (R&D) spending declined 11% to $2.5 million, reflecting lower compensation as resources shifted toward commercial growth. Selling, general, and administrative (SG&A) costs (GAAP) increased 11% to $23.4 million, driven mainly by higher employee compensation, travel, and non-cash stock-based grants, with some relief from lower advertising costs. The higher SG&A, while outpaced by revenue growth, resulted in operating and net losses that remain substantial—operating loss (GAAP) at $14.4 million and net loss (GAAP) at $14.7 million. Multiple reimbursement milestones provided stability for Barostim's future. The Centers for Medicare & Medicaid Services (CMS) proposed to retain Barostim as a covered outpatient procedure at the $45,000 payment level, removing some uncertainty for hospitals and ensuring continued access. In addition, CMS proposed favorable physician payment levels of about $550 for new procedure coding effective in 2026. On the clinical front, highlighted real-world data presented at major cardiology conferences showed large reductions in heart failure hospital visits—down 85% for heart failure, 84% for cardiovascular causes, and 86% for all causes—after Barostim implantation, based on comparisons of hospital visits for 306 Barostim patients in the 12 months prior to implant and an average of almost two years post-implant. These real-world results have been well received by physicians and payers, which it views as an important driver of payer support and future uptake. Furthermore, the company is preparing a large pragmatic randomized controlled trial (RCT), potentially enrolling up to 2,000 patients, to further establish Barostim's efficacy, as discussed in recent management commentary. Although the timing and costs of that effort depend on regulatory approval and payer support, management sees it as a long-term enabler of broader use. The company finished the quarter with $95.0 million in cash and cash equivalents, down from $105.9 million at year end 2024. Net cash used for operations and investing was $8.0 million, showing some improvement from $10.2 million a year ago, but still indicating ongoing cash burn. Long-term debt remained steady at $49.4 million. Looking Ahead: Guidance and Watch Items For fiscal 2025, management narrowed its revenue guidance to $55.0–$57.0 million, tightening the prior range and signaling increased confidence from better visibility into commercial results. The company expects gross margin to remain high at 83–84%. Operating expenses are now projected at $96.0–$98.0 million, a slight increase at the midpoint, reflecting ongoing investments in sales and account growth. Revenue is expected in the range of $13.7–$14.7 million for the next quarter, suggesting continued double-digit revenue growth ahead, as evidenced by a 15% year-over-year increase. Areas to watch in the coming quarters include progress in adding new implanting centers, the effectiveness and productivity of the enlarged sales force, and movement toward scaling revenues faster than expenses. Investors will also monitor any shift in European procedure volumes, cash usage trends, and the company's progress on the planned large RCT, as this trial could both validate Barostim's utility and expand the addressable market if successful. CVRX does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,019%* — a market-crushing outperformance compared to 178% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025
Globe and Mail
2 hours ago
- Globe and Mail
AGL Investors Have Opportunity to Join agilon health, inc. Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of agilon health, inc. ('Agilon' or 'the Company') (NYSE: AGL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Agilon announced on August 4, 2025, that President and CEO Steven Sell was stepping down immediately. The Company also withdrew its full-year 2025 financial guidance. Based on this news, shares of Agilon fell by more than 27.2% in after hours trading on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Globe and Mail
2 hours ago
- Globe and Mail
Ambiq Micro's IPO Could Signal the Next Wave of AI-Driven Chip Stocks
Key Points Ambiq Micro debuted to much fanfare on the first day of trading following its highly touted IPO. The company is a pioneer in ultra-low-power semiconductors used at the edge. While Ambiq Micro's future looks bright, that are potential risks investors shouldn't ignore. 10 stocks we like better than Ambiq Micro › Since generative artificial intelligence (AI) burst on the scene more than two years ago, some of the biggest beneficiaries have been chipmakers. More specifically, advanced semiconductors provide the computational horsepower necessary to breathe life into these AI algorithms. Nvidia, Broadcom, and Arm Holdings have all been at the forefront of AI chip design and reaped the rewards. Nvidia and Broadcom stocks have soared 961% and 439%, respectively, since late 2022, while Arm has gained 173% since its September 2023 initial public offering (IPO). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Ambiq Micro (NYSE: AMBQ) made a big splash during its public debut, as the low-power chip designer's stock surged 61% on its first day of trading last Wednesday, though it has since leveled off. Investors have been keen to profit from the ongoing adoption of AI, and the robust demand for Ambiq Micro stock suggests that power-miserly AI chip stocks could mark the next frontier. The power conundrum One of the biggest challenges associated with the increasing adoption of AI is the issue of power consumption. Most chipmakers have taken a brute-force approach, increasing the sheer magnitude of computational horsepower to decrease the time necessary to train and run these next-generation algorithms. The complex calculations required are computationally intensive, resulting in an increasing amount of energy consumption. Ambiq is taking a different approach. In the S-1 filed with the Securities and Exchange Commission (SEC) prior to its IPO, the company described itself as a "pioneer and leading provider of ultra-low-power semiconductor solutions designed to address the significant power consumption challenges of general-purpose and AI compute -- especially at the edge." Ambiq suggests its hardware and software innovations "deliver two to five times lower power consumption than traditional semiconductor design." The company is currently focused on the edge, including personal devices, as well as the medical and healthcare industries. Many of these applications are currently handled by small devices with limited battery life, where reduced power consumption is critical. In the future, Ambiq is working to expand its ultra-low-power technology to other areas of AI, including high-performance computing (HPC), data centers, and automotive, which could mark the next wave of AI chip solutions. A growing opportunity The need for power-miserly solutions could usher in the next wave of AI chips, and Ambiq's results are intriguing. For the year ended Dec. 31, the company generated revenue of $76 million, up 16% year over year, while its loss per share of $113.81 improved 24%. The trend continued in the quarter ended March 31, as revenue of $15.7 million climbed 3%, while its loss per share of $18.96 improved 30%. There is a significant concentration risk. Ambiq divulged that its top five customers accounted for 92% of revenue in the most recent quarter. Furthermore, wireless device specialist Garmin, Alphabet 's Google, and "another confidential customer" represented 38%, 25%, and 23% of net sales, respectively, according to its regulatory filing. Ambiq's flagship system-on-a-chip (SoC) is designed for smaller form-factor devices, such as smartwatches, fitness trackers, hearing aids, virtual and augmented reality glasses, and livestock tracking devices. Chief technology officer (CTO) Scott Hanson noted the company's next frontier is smart glasses. "We spent the last 10-plus years figuring out how to build the lowest power chips, and so we're in a great position to attack the same problem (on glasses)," he said. The low-power wearable chips market is expected to grow by 15% annually between 2024 and 2030 to nearly $28 billion. When viewed in the context of Ambiq's 2024 sales of $76 million, the opportunity is apparent. Every rose has its thorns It's important to remember that while Ambiq's potential is clear, risks abound. It has only just entered the glare of the public spotlight, and investors should keep in mind the aforementioned concentration risk and mounting losses, though its results are moving in the right direction. There's also the matter of Ambiq's valuation. As of market close on Monday, the stock had a market cap of roughly $673 million and trailing-12-month sales of $76.6 million. That works out to about 9 times sales, and while that's certainly not outrageous, it is a high price to pay for an unprofitable company with little public track record. As such, investors interested in taking a stake in this ultra-low-power pioneer should make Ambiq a small part of a well-balanced portfolio. Should you invest $1,000 in Ambiq Micro right now? Before you buy stock in Ambiq Micro, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ambiq Micro wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* *Stock Advisor returns as of August 4, 2025
